Trial Profile

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rocapuldencel T (Primary) ; Sunitinib
Indications Renal cell carcinoma
Focus Therapeutic Use
Sponsors Argos Therapeutics Inc

Most Recent Events

21 Apr 2015 Results published in the Journal for ImmunoTherapy of Cancer, according to a Argos Therapeutics Inc media release.
18 Sep 2014 Results published in Argos Therapeutics media release.
14 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to an Argos Therapeutics media release. Results were also briefly summarised in the media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com